By submitting this form, you are agreeing to the Terms of Use and Privacy Policy.
Parkinson’s disease symptoms are treated with rasagiline alone or in conjunction with other drugs (a slowly progressing disease of the nervous system causing a fixed face without expression, tremor at rest, slowing of movements, walking with shuffling steps, stooped posture and muscle weakness).
Rasagiline is a member of the monoamine oxidase (MAO) type B inhibitors drug class. It functions by raising the levels of specific organic compounds in the brain.
Negative effects-It’s possible to have lightheadedness, drowsiness, joint discomfort, heartburn, nausea, dry mouth, weight loss, or stomach/abdominal pain. Inform your physician or pharmacist right away if any of these side effects persist or worsen.
It is used either alone or in conjunction with other drugs (such levodopa/carbidopa) to treat the symptoms of Parkinson’s disease.
It can alleviate signs including trembling, stiffness, and trouble moving. Additionally, it can help to cut down on “off” time (periods of slow movement or stiffness). Rasagiline is a type of drug known as an MAO inhibitor.
It functions by increasing the levels of specific natural chemicals in the brain (such as dopamine, norepinephrine, serotonin).
The effects of one medicine last about a week, whereas those of another last around two weeks. However, over the course of eight weeks, people see a noticeable improvement in their symptoms. Take the medication at the same time each day to get the best outcomes.
Global RASAGILINE market accounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.
Rasagiline Tablets, 0.5 mg and 1 mg, a generic version of the reference listed medication, Teva’s Azilect Tablets, was made available in the United States by Mylan N.V.
The U.S. Food and Drug Administration (FDA) granted final approval to Mylan’s Abbreviated New Drug Application (ANDA) for this medication, which is indicated for the treatment of Parkinson’s disease.
The multinational pharmaceutical business Mylan is dedicated to raising the bar for healthcare. Working together globally to give people access to high-quality healthcare, they innovate to fill unmet needs, practise dependability and service excellence, behave morally rather than expediently, and have a positive impact on the future through committed global leadership.
The US Food & Drug Administration has given final approval to Indoco Remedies’ Abbreviated New Drug Application (ANDA) for Rasagiline 0.5 mg and 1 mg tablets (USFDA). Parkinson’s disease is treated with rasagiline. The size of this product’s US market.
